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Abstract 
 
Objective: To conduct the first and only systematic review of the existing literature on head and 
neck manifestations of Eosinophilic Granulomatosis with Polyangiitis in order to guide clinical 
decision making for the otolaryngologist.  
Data Sources: PubMed, Cochrane Library, Scopus and LILACS. Review Methods: A systematic 
review of the aforementioned sources was conducted per PRISMA guidelines. Results: From an 
initial 574 studies, 28 trials and reports accounting for a total of 1,175 Eosinophilic Granulomatosis 
with Polyangiitis patients were included.  Amongst clinical and cohort studies, 48.0% to 96.0% of 
all included patients presented with head and neck manifestations.  In a distinct group of patients 
detailed in case reports describing patients presenting with head and neck manifestations on aver-
age fulfilled 4.6 American College of Rheumatology diagnostic criteria. Further, 95.8% of re-
ported cases were responsive to steroids and 60% required additional therapy. Conclusion: Otolar-
yngologists are in a unique position for the early diagnosis and prevention of late complications of 
Eosinophilic Granulomatosis with Polyangiitis.  The American College of Rheumatology criteria 
should be relied upon in the diagnostic work-up.  Close surveillance of these patients in a multi-
disciplinary fashion and with baselines CBCs, chest radiographs and autoimmune labs is often 
necessary. Such patients with head and neck manifestations of the disease are nearly always re-
sponsive to steroids and often require additional immunosuppressive therapy or surgical interven-
tion in cases of cranial neuropathies, temporal bone involvement and refractory symptoms.  
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Introduction 
 
Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome, 
is a rare systemic vasculitis affecting small and medium-sized vessels of the paranasal sinuses, 
lungs and nervous system.  Initial presentations of EGPA often present with clinical profiles ref-
erable to otolaryngology departments.  Otolaryngologists are consequently in a unique position to 
diagnose the disease early and prevent late complications. Due to the potential for extensive head 
and neck involvement, it is crucial for otolaryngologists to recognize EGPA's characteristic 
presentation and play a chief role in the interdisciplinary approach to management.  To date there 
have been limited reviews of the literature highlighting generalized patient experiences and rare 
presentations of EGPA with an otolaryngologic focus.  
 
EGPA clinically manifests in three delineated stages.  The disease classically will first present in 
a prodromal stage which is characterized by asthmatic episodes, allergic rhinitis, rhinosinusitis and 
occasional nasal polyps.1  EGPA's second phase will present with peripheral eosinophilia and eo-
sinophilic infiltration of tissues.2 Lastly, EGPA's third phase will manifest with polyneuropathies 
secondary to systemic vasculitis.2 Late debilitating and fatal manifestations of EGPA include: my-
ocarditis, sudden cardiac death, cerebral hemorrhages, ischemic strokes and bowel perforations.2  
As this disease course may persist or recur for several years, an otolaryngologist is afford a large 
window of time to monitor symptoms and make the diagnosis of EGPA.  However this diagnosis 
may be difficult due to its variable presentation and lack of definitive objective tests to rule the 
disease in or out. 
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Historically multiple organizations have defined EGPA differently; however, the American Col-
lege of Rheumatology's (ACR's) classification criteria has been widely accepted since the 1990's.  
According to the ACR, in order to be classified as EGPA an individual must present with at least 
four of six distinct findings: 1) a medical history of asthma, 2) eosinophilia of greater than 10%, 
3) mono- or polyneuropathy, 4) non-fixed pulmonary infiltrates, 5) paranasal sinus abnormalities, 
or 6) biopsy including an artery, arteriole or venule documenting accumulated eosinophils in ex-
travascular tissue.3  
 
The objective of this systematic review is to review the current literature on EGPA and its oto-
laryngologic manifestations as well as investigating the role of the otolaryngologist to assist in 
early detection of disease.  To the authors' knowledge this is the first and only systematic review 
of EGPA with a focus on head and neck manifestations. 
 
Methods 
 
Search strategy and selection 
 
We conducted a focused literature review targeting the otolaryngological clinical presentations, 
diagnosis, treatments and outcomes of patients with EGPA.  The systematic review was conducted 
per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guide-
lines.4  Studies were evaluated by four independent reviewers in order to minimize appraisal bias. 
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Study eligibility and selection criteria were predefined to include: large study groups of general 
EGPA patients or case reports of EGPA patients with head and neck presentations.  For the pur-
poses of this review, diagnosis of EGPA was dependent upon meeting the ACR definition of the 
disease.  
 
Only those clinical trial and cohort reviews that included a generalized EGPA population in which 
those patients with specific head and neck manifestations were identified and distinguished were 
to be included.  Case series and reports of interest would include head and neck manifestations 
meeting the above inclusion criteria.  
 
In March 2016 a search was initiated via PubMed, Cochrane Library, Scopus and LILACS data-
bases.  Key terms and their derivatives included: otolaryngology, ear, nose, throat, laryngology, 
rhinology, otology, cranial nerves, parotid, submandibular gland, sublingual gland, mastoid, para-
nasal sinuses, neck, churg-strauss syndrome, and eosinophilic granulomatosis with polyangiitis. 
 
Search catalogs were collected and imported into RefWorks software.  Exact and close duplicates 
were detected and manually reviewed for accuracy before deletion of repeated studies.  Concerns 
and discrepancies regarding study relevancy between reviewers were discussed amongst all au-
thors to reach a consensus if necessary. 
 
Titles and abstracts of all search results were thoroughly reviewed for relevance and eligibility.  
Studies were screened and excluded based upon being: non-head and neck presentations, non-
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English without available translation or non-EGPA specific studies. Studies in question were re-
viewed in full-text for clarity and excluded based on: overlapping patient populations, insufficient 
data, unavailable English full text, or failing to fulfill ACR criteria. 
 
Data collection 
Due to the rarity of head and neck manifestations of EGPA data was collected and organized into 
two distinct subsets: clinical trials or cohort studies and case report experiences. When available 
the following patient information was independently extracted from the relevant clinical trial and 
cohort studies: means of selection, population size, mean age, gender, head and neck manifesta-
tions, nasal and paranasal sinus histology, ANCA status, treatment and outcome.   
 
Case series and reports meeting inclusion criteria were reviewed for and had the following data 
extracted: age, gender, ACR criteria met, non-paranasal head and neck manifestations, ANCA 
status, treatment and outcome.  When available the source of extravascular eosinophilia and his-
tology was noted.  Treatment methods were further divided to steroidal and non-steroidal inter-
ventions.   Outcomes were recorded with a focus on response to given therapy.  
 
Included studies were evaluated in terms of study design, level of evidence and risk of bias.  Level 
of evidence was determined by the Oxford Centre for Evidence-Based Medicine 2011 Levels of 
Evidence.5  Risk of bias were assessed using the Cochrane Collaboration's tool for assessing risk 
of bias for a grading of low, high or unclear risk of bias.6 
 
Results 
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Study Results 
 
In our search we collected a total of 574 articles through the above named databases along with 
additional articles identified through references of seed studies used in introductory background 
research.  Ultimately the results of 1 clinical trial, 6 retrospective cohort studies, 2 prospective 
cohort studies, 2 case series and 17 case reports accounting for a total of 1,175 EGPA patients 
were included for systematic review.7-34 
 
Figure 1. PRISMA flow diagram for study inclusion 
 
Table 1. Included study designs, levels of evidence and biases 
 
As seen in table 1, of the 28 studies meeting our inclusion criteria levels of evidence ranged from 
2 to 4.  Risk of bias was either low or unclear in all studies.  Unclear risk of bias presented as 
attrition bias due to insufficiently addressed incomplete outcome data in 3 studies.  Reporting bias 
was unclear in 2 studies that provided insufficient clinical selection criteria. 
 
Clinical trial and cohort study results  
 
Table 2. Clinical trial and cohort study designs, demographics and symptoms 
 
As seen in table 2, individual study patient population sizes ranged from 28 to 383 with a median 
of 101 patients.  The mean age of patient populations ranged from 49.1 to 51.9.  Male to female 
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ratio ranged from 58:43 to 39:54.  Of these patients, documented head and neck manifestations 
included: various rhinologic conditions including sinusitis, nasal polyps, rhinitis nasal crusting and 
nasal obstruction along with otitis media, sensorineural hearing loss and facial nerve palsies.  Of 
the total number of patients included in each individual study, 48.0% to 96.0% of patients pre-
sented with some head and neck involvement.   
 
Table 3. Clinical trial and cohort study diagnostic findings, treatments and outcomes 
 
As highlighted in table 3, patients with documented nasal or paranasal sinus biopsies demonstrated 
eosinophilic infiltration in 35% to 100% of samples.  None of said biopsies had evidence of ne-
crotizing vasculitis or eosinophilic granulomas.  In these studies, the presence or absence of a 
blood vessel was not noted.  Additionally the site of the biopsy collected was not specified beyond 
the general categories of “nasal cavity and paranasal sinuses” or “sinus or nasal mucosa”.9,10   
 
All patients in each population received some form of steroids.  Cyclophosphamide was the second 
most common offered therapy and received in 49.5% to 71% of cases in which documentation was 
available.  Additional common therapies included: azathioprine, methotrexate, rituximab, myco-
phenolate mofetil, intravenous immunoglobulin, leflunomide, anti-TNF alpha and plasma ex-
change.  Insufficient data was available to be extracted regarding medication choice or dosage to 
correlate therapy with clinical presentation and outcome. 
 
Case series and reports results  
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Nineteen publications accounted for 25 total patients with unique head and neck manifestations.  
Included patients had a mean age of 52.16 and male to female ratio of 2:5.  Patients presented 
meeting an average of 4.6 ACR criteria.  All but 1 patient presented with evidence of asthma and 
90% of patients presented with extravascular eosinophilia on histology. Paranasal sinus abnormal-
ities, eosinophilia, neuropathy and non-fixed pulmonary infiltrates presented in 88.%, 88.0%, 
56.0%, and 48.0% of patients respectively.  Of patients identified, 17 had known ANCA status of 
which 64.7% were ANCA positive.   
 
Head and neck manifestations varied greatly and involved all systems.  Such presentations in-
cluded: recurrent laryngeal polyposis, anosmia, mastoiditis, intracranial abscesses and a diversity 
of cranial neuropathies.  In the evaluation of these patients, extravascular eosinophilic histology 
was demonstrated in a diversity of head and neck specific biopsy sites as described by the case 
reports and series authors such as: laryngeal polyps, the ethmoid sinus, salivary glands and the 
mastoid.28, 17, 25  In meeting ACR criteria, mastoid biopsies revealed eosinophilic granulomatous 
tissue while histology was limited to only eosinophilic infiltration or necrosis in all other above 
noted head and neck sites.   
 
All but one (96.0%) of included patients with sufficient data received steroids and were found to 
be responsive in 95.8% of cases.  Prednisone was the most commonly offered steroid (56.0%) 
followed by methylprednisolone (24.0%).  The most common inducing dose of prednisone was 60 
mg daily and tapered dosages ranged from 4 mg to 10 mg daily.  Inducing dosages were adminis-
tered from 5 days to 6 weeks. Additional medical or surgical therapy was offered in 56.0% of 
cases.  Additional immunosuppressant therapy including cyclophosphamide, azathioprine and 
methotrexate were provided in 28.0% of cases.  All included patients had either stabilization or 
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resolution of presenting symptoms. Of the 5 patients receiving cyclophosphamide 3 had resolution 
of symptoms, 1 experienced partial resolution of symptoms and 1 died of secondary pulmonary 
infection. Of the 3 patients receiving azathioprine, 2 achieved remission and 1 experienced partial 
resolution of symptoms.  The 1 patient treated with methotrexate had resolution of symptoms at 1 
year. 
 
 
Discussion 
 
From its seemingly indolent initial presentations to its debilitating advanced cardiac, neurological 
and gastrointestinal manifestations, the diagnosis and treatment of EGPA poses a clinical challenge 
to otolaryngologists.  Through reviewing the existing literature we were able to construct a clinical 
profile of EGPA patients presenting with head and neck manifestations both common and rare.  
Data was extracted through 28 studies of varied designs including: clinical trials, prospective and 
retrospective cohort studies along with cases series and reports.  Levels of data ranged from 2 to 4 
with varying degrees of bias risk.  Our review was potentially limited by the inherent quality of 
included studies.  Many of the studies in the field were observational and pooled from various 
patient databases.  Patient populations may be influenced by level of disease severity as well as 
the subsidiary medical departments being referred to at each medical center. 
 
Patient group populations were consistent in age and gender ratios to one-another and previous 
reports.35  Study samples had large variations in proportion of patients with head and neck mani-
festations.  Differences may be attributed to the varied departments referred to within each group 
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or the definitions of head and neck manifestations by each study.  Further, ANCA positive status 
varied.  A majority of studies failed to demonstrate an association between patients with head and 
neck manifestations and ANCA status compared to the general EGPA population.  This suggests 
that while a positive ANCA status may be helpful in the work-up of EGPA, it is often negative, 
not required in establishing a diagnosis of EGPA and has an unclear role in the head and neck 
phenotype of EGPA patients. 
 
Case reports described varying degrees of severity and unique presentations of EGPA.  These 
patients on average exceeded the minimum diagnostic criteria per the ACR guidelines suggesting 
that a CBC, PFT, EMG, tissue biopsy and full head and neck physical exam are all potentially 
necessary in the diagnosis of EGPA. 
 
In all studies reviewed, no nasal or paranasal sinus biopsies revealed any eosinophilic granulomas 
and only one demonstrated evidence of necrotizing vasculitis.  It is important to note that while 
EGPA is regarded as a vasculitis, biopsies are often marked by a non-destructive eosinophilic 
vessel wall infiltration.36  While many did demonstrate an eosinophilic infiltration, this is a com-
mon histologic finding of upper airway tissue in atopic disease processes.  
 
In understanding the questionable significance of biopsy findings, otolaryngologists would benefit 
from more objectively defined diagnostic guidelines.  Although it is stated in the ACR guidelines 
that a blood vessel is necessary to be included in a biopsy, further elaboration would assist in 
diagnosing EGPA.  For instance a minimum eosinophil concentration, an eosinophil to neutrophil 
ratio, a maximum eosinophil proximity to the vessel and a defined eosinophil pattern in relation-
ship to the vessel would assist in determining the context of a sample.  These descriptions would 
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also help define the significance of “eosinophilic infiltration” and “extravascular eosinophils” 
which are not currently objectively defined in guidelines. 
 
In the setting of equivocal histopathologic findings, an otolaryngologist should also look for con-
comitant eosinophilia, a longstanding history of refractory or adult onset asthma and sinusitis along 
with any neuropathies.  Moreover, even if nasal or paranasal sinus biopsy demonstrates extravas-
cular eosinophilic histology, one should consider further biopsies when additional body system 
involvement is suspected to further substantiate the nasal and paranasal sinus findings.  Of note, 
some authors have broadened the diagnostic threshold by proposing the limited form of EGPA.  
Such cases highlight presentations which fail to fulfill the clinical and histopathological character-
istics of EGPA.37  Although this concept is applied to earlier diagnostic criteria, it is important to 
recognize EGPA defined by the ACR criteria as a disease which exists on a continuum.  Moreover, 
as otolaryngologists often encounter patients in the earlier prodromal stages of EGPA, neuropa-
thies and eosinophilia may not yet be present.  
 
Given our finding that eosinophilia and pulmonary infiltrates are common manifestations which 
follow asthma and polyposis, we recommend evaluation with a pre-operative or outpatient CBC 
with differential as well as a chest radiograph in the presence of any pulmonary symptoms to 
provide a baseline for patients with a high index of suspicion.  Additionally we recommend basic 
autoimmune labs including ANA and ANCA in such patient.  Although not a component of the 
ACR criteria or directly associated with head and neck manifestation severity, autoimmune find-
ings are effective in ruling out other vasculitides and narrowing a diagnosis of EGPA. We also 
recommend when such patients undergo FESS for nasal polyposis, close communication with pa-
thology is necessary to ensure the inclusion of blood vessels, to closely evaluate for eosinophilic 
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patterns and to rule out infection or malignancy.  Due to the prevalence of chronic rhinosinusitis 
with polyposis in many otolaryngology practices, a multidisciplinary approach is often necessary 
prior to such a work-up.  A benefit risk assessment is a strong area for future study given the 
constraints of the existing data. 
 
In the treatment of patients with head and neck manifestations we see that nearly all were respon-
sive to steroids and often required additional immunotherapy or surgical interventions.  Ninety six 
percent of patients received some form of steroid.  Patients on steroids alone had resolution of both 
clinical symptoms and laboratory abnormalities in 14 of 16 (87.5%) of cases.  A common recom-
mendation involved initial inducing dosages of 1 mg/kg of prednisone daily for 1 to 6 months then 
tapered to 4 to 10 mg of prednisone daily. 
 
Patients with refractory symptoms, neuropathies and those with temporal bone involvement often 
required additional immunosuppressive therapy.  The most common additional therapy offered 
with cyclophosphamide, often received in 6 to 12 pulses.  Other immunosuppressants included 
azathioprine, methotrexate, rituximab and mycophenolate mofetil. Those receiving additional im-
munotherapy had resolution in 5 of 8 (62.5%) cases.   
 
Ultimately, despite medical management trends, inadequate dosing and response information ex-
ists in drawing definitive recommendations for both steroid and immunosuppressive therapies.     
Additionally, future studies would benefit from objectively defining response to therapy and with 
consideration to biologic markers 
 
Conclusion 
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Given the diagnostic challenge of EGPA, an otolaryngologist must maintain a high index of sus-
picion for the disease given its characteristic constellation of laboratory values, histologic findings 
and clinical manifestations which in isolation are often seemingly ubiquitous.  Early diagnosis and 
treatment through multidisciplinary collaboration amongst otolaryngologists on the front line of 
treatment along with pulmonologists, allergists, immunologists, pathologists and rheumatologists 
is key in preventing widespread neuropathies and multi-system involvement.  
 
Based on our review of previous otolaryngologists’ experiences with EGPA, we recommend that 
patients presenting with both nasal polyposis and asthma undergo further investigation.  Increased 
suspicion should be given to those patients with adult-onset asthma, poorly controlled asthmatic 
symptoms and those with recurrent nasal polyposis despite corticosteroid or surgical interventions.  
 
 Given our finding that eosinophilia and pulmonary infiltrates are common manifestations which 
follow asthma and polyposis, we recommend evaluation with a pre-operative or outpatient CBC 
with differential as well as a chest radiograph in the presence of any pulmonary symptoms to 
provide a baseline for the patient.  Additionally we recommend basic autoimmune labs including 
ANA and ANCA in such patients with a high suspicion for EGPA.  Although not a component of 
the ACR criteria or directly associated with head and neck manifestation severity, autoimmune 
findings are effective in ruling out other vasculitides and narrowing a diagnosis of EGPA.  We 
also recommend when such patients undergo FESS for nasal polyposis, close communication with 
pathology is necessary to ensure the inclusion of blood vessels, to closely evaluate for eosinophilic 
patterns and to rule out infection or malignancy. 
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Ultimately EGPA is a rare process and little data exists in specifically guiding the otolaryngologic 
management of this disease.  This is the first only systematic review of the existing literature with 
a head and neck focus.  Due to a paucity of existing data for meta-analysis a treatment algorithm 
or dosage recommendations for corticosteroid and antimetabolite treatment cannot be reached at 
this time and is a fertile area for future study. 
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Table 1. Included study designs, levels of evidence and biases 
 Study Type Level of Evidence Risk of Bias 
Al-Ammar (2009) Case report 4 Low 
Anar (2011) Case report 4 Low 
Bacciu (2006) Retrospective cohort study 3 Low 
Bili (1999) Case series 4 Unclear reporting bias 
Boin (2006) Case report 4 Low 
Comarmond (2013) Retrospective cohort study 3 Unclear attrition bias 
Durel (2015) Retrospective cohort study 3 Low 
Fernandes (2014) Case report 4 Low 
Healy (2012) Retrospective cohort study 3 Unclear attrition bias 
Ishiyama (2001) Case series 4 Low 
Martinez Del Pero (2008) Case report 4 Low 
Moor (2002) Case report 4 Low 
Moosig (2013) Retrospective cohort study 3 Low 
Ovidia (2009) Case report 4 Low 
Park (2015) Case report 4 Low 
Ribi (2008) Clinical trial 2 Unclear reporting bias 
Sablé-Fourtassou (2005) Prospective cohort study 3 Unclear attrition bias 
Saka (2007) Case report 4 Low 
Samson (2013) Prospective cohort study 3 Low 
Sinico (2005) Retrospective cohort study 3 Low 
Tallab (2014) Case report 4 Low 
Trovoli (2013) Case report 4 Low 
Visentin (2012) Case report 4 Low 
Ozaki (2012) Case report 4 Low 
Plaza (2001) Case report 4 Low 
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Sale (1981) Case report 4 Low 
Byun (2014) Case report 4 Low 
Mazzantini (1997) Case report 4 Low 
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Table 2. Clinical trial and cohort study designs, demographics and symptoms 
  
Selection 
Patients 
(n) 
Mean 
age 
Gender 
male/ 
female 
ENT 
Involvement 
no. (%) ENT Manifestations 
Bacciu 
(2006) 
Retrospective review of all 
CSS patients in single study 
group from 1997 to 2004. 28 51.3 11/10 21 (75%) 
Allergic rhinitis, sinusi-
tis, nasal polyps, otitis 
media, SNHL, facial 
nerve palsy 
Comar-
mond 
(2013) 
Retrospective review of pa-
tients in a single cohort from 
1957 to June 2009 383 50.3 
199/18
4 184 (48.0%) 
Sinusitis, rhinitis, nasal 
polyps 
Durel 
(2015) 
Retrospective review of pa-
tients identified in 3 tertiary 
centers databases for from 
1990 to 2011 101 49.2 58/43 97 (96.0%) 
Sinusitis, rhinitis, nasal 
polyps, nasal obstruction 
Healy 
(2012) 
Retrospective review of cases 
reported to FDA from 1997 to 
2003 93 - - 59 (63.4%) Sinusitis 
Moosig 
(2013) 
Retrospective cohort study of 
cases documented at a single 
referral center from 1990 to 
2009 150 49.1 76/74 140 (93.3%) 
Sinusitis, nasal mucosa 
inflammation, nasal 
polyps, middle ear infec-
tion 
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Ribi 
(2008) 
Multicenter screening of pa-
tients diagnosed with CSS 
from 1994 to 2005. 72 51.7 38/34 50 (69.4%) Sinusitis 
Sablé- 
Fourtassou 
(2005) 
Multi-center cohort study of 
French Vasculitis Study 
Group and European Vascu-
litis Study Group patients en-
rolled in prospective trials 
from 1995 to 2002. 112 52 55/57 83 (74.1%( 
Sinusitis, rhinitis, nasal 
polyps, nasal obstruction 
Samson 
(2013) 
Clinical reports of patients en-
rolled in 2 prospective, ran-
domized open label clinical 
trials from 1994 to 2005) 118 51.9 64/54 88 (74.6%) Sinusitis, crusting, otitis 
Sinico 
(2005) 
Retrospective review of 
ANCA tested patients identi-
fied among internal medicine 
departments in 4 general hos-
pitals from 1989 to 2004. 93 51.6 39/54 72 (77.4%) Sinusitis 
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Table 3. Clinical trial and cohort study diagnostic findings, treatments and outcomes 
 
ANCA+: 
No. All (%) 
No. ENT (%) 
Nasal and paranasal 
sinus biopsies Treatment Outcome 
Bacciu  
(2006) 
- 
10 (47.6%) 
5: 100% eosino-
philic polyposis or 
infiltrates. 
-CS and nonspecified immu-
nosuppressive treatment in 
all cases 
-No head and neck manifesta-
tion relapses; no mortalities. 
Comar-
mond 
(2013) 
108 (28.2%) 
64 (34.8%) 
23: 35% granu-
loma, necrotizing 
vasculitis or eosino-
philic infiltration. 
-383 CS, 217 CYP; 98 AZA; 
26 MTX; 3 rituximab. 
-Vasculitis relapse in 97; 
asthma flares, sinusitis or in-
creased eosinophilia in 72; 
236 required maintenance CS 
Durel  
(2015) 
43 (42.5%) 
41 (42.3%) - 
-101 CS; 45 CYP.  
-Maintenance therapy: 29 CS 
alone; 24 AZA; 22 rituxi-
mab; 15 mycophenolate mo-
fetil; 1 MTX;1 IVIg -74 with complete remission. 
Healy  
(2012) 
15 (16.1%) 
9 (15.3%) - - - 
Moosig  
(2013) 
45 (30%) 
41 (29.3%) - 
-150 CS; 107 CYP; 105 
MTX; 49 AZA; 32 lefluno-
mide; 17 interferon alpha; 10 
anti-TNF alpha; 1 rituximab; 
5 IVIg. -70 in remission. 
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Ribi  
(2008) 
29 (40.3%) 
- (-%) 
13: 9 eosinophilic 
infiltration. -72 CS; 10 AZA; 9 CYP. 
-77 on CS; 5 on AZA and 7 on 
CYP with remission. 
Sablé- 
Fourtassou  
(2005) 
43 (38.4%) 
36 (43.4%) - 
-Mild disease: CS alone  
-Severe disease received 
steroids along with 6 to 12 
pulses of CYP therapy. -102 in remission. 
Samson  
(2013) 
48 (40.7%) 
- (-%) - 
-Mild disease CS alone  
-Severe disease CS with 6 to 
12 pulses of CYP. 
-34 in remission. Overall sur-
vival of 90% at 7 years. 
Sinico  
(2005) 
35 (37.6%) 
27 (37.5%) - 
-93 CS; 42 CYP; 5 MTX, 1 
AZA, 1 IVIg; 4 and plasma 
exchange. - 5 year survival rate of 95.1% 
Abbreviations: ANCA+, Anti-neutrophil cytoplasmic antibody positive; AZA, Azathioprine; CS, corticosteroids; 
CYP, cyclophosphamide; IVIg, intravenous immunoglobulin; MTX, methotrexate 
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Figure legend 
 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow 
diagram for study inclusion and exclusion. 
